Market Place
Company
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Developments Endocrinology Phase III
Details:
The 12-week trial enrolled 32 patients (with 30 patients completing) and demonstrated that ORMD-0801 (insulin) was safe and well tolerated at 8 mg twice daily dosing, meeting the primary endpoint of no difference in adverse events for ORMD-0801 compared to placebo.
Lead Product(s): Insulin
Therapeutic Area: Endocrinology Product Name: ORMD-0801
Highest Development Status: Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
PTH replacement therapy with TransCon PTH (palopegteriparatide) was well-tolerated through Week 110, with continued normalization of mean urine calcium and no discontinuations from the trial due to adverse events.
Lead Product(s): Palopegteriparatide
Therapeutic Area: Endocrinology Product Name: TransCon PTH
Highest Development Status: Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
